ArticleAsian journal of neurosurgery2026
Factors Affecting Chronic Subdural Hematoma Recurrence after Middle Meningeal Artery Embolization.
Article in Asian journal of neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Middle meningeal artery embolization in chronic subdural hematoma: a paradigm shift?European radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Although the predictors of chronic subdural hematoma (SDH) recurrence after surgical evacuation are well known, there is limited evidence available on factors affecting its recurrence after middle meningeal artery (MMA) embolization. The objective of this study was to determine the factors influencing the risk of recurrence in patients with chronic SDH undergoing MMA embolization. Materials and Methods: A prospective study was performed between September 2022 and October 2024 on patients with chronic SDH who underwent MMA embolization with or without surgical evacuation. The primary outcome was clinical recurrence of SDH within 90 days after the embolization, defined as new onset or worsening of existing neurological symptoms, associated with a residual or recurrent SDH with hyperdense contents on computed tomography (CT). Statistical Analysis: The association of demographic, clinical, imaging, and angiographic parameters with SDH recurrence was analyzed. For variables that showed a significant association with recurrence, relative risks were ascertained. All statistical tests were two-sided, and a Results: Seventy-four patients (mean age, 67.3 ± 11 [standard deviation] years; males, 66/74 [89.2%]) with 96 SDHs were included in the study. Clinical recurrence of chronic SDH was observed in 6 patients (8.1%). Membrane enhancement on pre-embolization CT was less common in hematomas that recurred than those that did not (2/8, 25% vs. 61/88, 69.3%; Conclusion: The absence of enhancement on pre-embolization CT is a risk factor for SDH recurrence after MMA embolization. The high recurrence rate in hematomas without membrane enhancement indicates that MMA embolization may not reduce the risk of recurrence in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.